Stefan Zeuzem
Goethe University Frankfurt
1147 Papers
11.1K Citations
Stefan Zeuzem is an academic researcher from Goethe University Frankfurt. The author has contributed to research in topics: Medicine & Ribavirin. The author has an hindex of 108, co-authored 1027 publications. Previous affiliations of Stefan Zeuzem include Max Planck Society & Saarland University.
Chat about Author
Papers
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)
Thierry Poynard,Patrick Marcellin,Samuel S. Lee,Christian Niederau,Gerald S. Minuk,Gaetano Ideo,Vincent G. Bain,Jenny Heathcote,Stefan Zeuzem,Christian Trepo,Janice K. Albrecht +10 more
TL;DR: AnInterferon α2b plus ribavirin combination is more effective than 48 weeks of interferonα2b monotherapy and has an acceptable safety profile and patients with few favourable factors benefit more from extending the duration of combination therapy to 48 weeks.
2.4K
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
Devin Razavi-Shearer,Ivane Gamkrelidze,Mindie H. Nguyen,Ding-Shinn Chen,Pierre Van Damme,Zaigham Abbas,Maheeba Abdulla,Antoine Abou Rached,Danjuma Adda,Inka Aho,Ulus Salih Akarca,Fuad Hasan,Faryal Al Lawati,Khalid Al Naamani,Hamad I. Al-Ashgar,Seyed M Alavian,Sameer Alawadhi,Agustín Albillos,Said A. Al-Busafi,Soo Aleman,Faleh Z. Al-Faleh,Abdulrahman Aljumah,Anil C. Anand,Nguyen Thu Anh,Joop E. Arends,Perttu Arkkila,Kostas Athanasakis,Abate Bane,Ziv Ben-Ari,Thomas Berg,Abdul Rahman Bizri,Sarah Blach,Carlos E Brandão Mello,Samantha M Brandon,Bisi Bright,Philip Bruggmann,Maurizia Rossana Brunetto,Maria Buti,Henry Lik-Yuen Chan,Asad Chaudhry,Rong-Nan Chien,Moon Seok Choi,Peer Brehm Christensen,Wan-Long Chuang,Vladimir Chulanov,Mette Rye Clausen,Massimo Colombo,Markus Cornberg,Benjamin C Cowie,Antonio Craxì,E. A. Croes,Diego Alberto Cuellar,Chris Cunningham,Hailemichael Desalegn,Sylvia Drazilova,Ann-Sofi Duberg,Steve S Egeonu,Manal H El-Sayed,Chris Estes,Karolin Falconer,Maria Lucia Gomes Ferraz,Paulo R. Ferreira,Robert Flisiak,Sona Frankova,Giovanni Battista Gaeta,Javier García-Samaniego,Jordan Genov,Jan Gerstoft,Adrian Goldis,Ilias Gountas,Richard Gray,Mario G. Pessoa,Behzad Hajarizadeh,Angelos Hatzakis,Christophe Hézode,Sayed Himatt,Andy I. M. Hoepelman,Irena Hrstić,Yee Tak Hui,Petr Husa,Rohani Jahis,Naveed Z. Janjua,Peter Jarcuska,Jerzy Jaroszewicz,Sabahattin Kaymakoglu,David Kershenobich,Loreta A. Kondili,Aliya Konysbekova,Mel Krajden,Pavol Kristian,Wim Laleman,Wai-cheung C Lao,Jen Layden,Jeffrey V. Lazarus,Mei Hsuan Lee,Valentina Liakina,Young-Suk Lim,Ching-kong K Loo,Boris Lukšić,Reza Malekzadeh,Abraham O. Malu,Adkhamjon Mamatkulov,Michael Manns,Rui Tato Marinho,Mojca Matičič,Stefan Mauss,Muhammad S. Memon,Maria C Mendes Correa,Nahum Méndez-Sánchez,Shahin Merat,Ammal M. Metwally,Rosmawati Mohamed,Jacques E Mokhbat,Christophe Moreno,Joël Mossong,Fadi H. Mourad,Beat Müllhaupt,Kimberly Murphy,Erkin Musabaev,Arif Nawaz,Helen Nde,Francesco Negro,Alexander Nersesov,Van Thi Thuy Nguyen,Richard Njouom,Renovat Ntagirabiri,Zuridin Nurmatov,Solomon Obekpa,Ponsiano Ocama,Stephen Oguche,Ogu Omede,CE Omuemu,Ohene Opare-Sem,Christopher K Opio,Necati Örmeci,George V. Papatheodoridis,Ken Pasini,N. N. Pimenov,Hossein Poustchi,Trân D Quang,Huma Qureshi,Alnoor Ramji,Kathryn Razavi-Shearer,Berhane Redae,Henk W. Reesink,Cielo Yaneth Rios,Gabriela Rjaskova,Sarah Robbins,Lewis R. Roberts,Stuart K. Roberts,Stephen D. Ryder,Rifaat Safadi,Olga Sagalova,Riina Salupere,Faisal M. Sanai,Juan Francisco Sánchez-Ávila,Vivek A. Saraswat,Christoph Sarrazin,Jonathan Schmelzer,Ivan Schréter,Julia A. Scott,Carole Seguin-Devaux,Samir Shah,Ala I. Sharara,Manik Sharma,Gamal Shiha,Tesia Shin,William Sievert,Jan Sperl,Peter Stärkel,Catherine A.M. Stedman,Vana Sypsa,Frank Tacke,Soek Siam Tan,Junko Tanaka,Krzysztof Tomasiewicz,Petr Urbánek,Adriaan J. van der Meer,Hans Van Vlierberghe,Stefano Vella,Adriana Vince,Yasir Waheed,Imam Waked,Nick Walsh,Nina Weis,Vincent Wai-Sun Wong,Joseph Woodring,Cesar Yaghi,Hwai I. Yang,Chung-Lin Yang,Kakharman Yesmembetov,Ayman Yosry,Man-Fung Yuen,Muhammed Aasim M Yusuf,Stefan Zeuzem,Homie Razavi +195 more
TL;DR: The estimate of HBV prevalence in 2016 differs from previous studies, potentially because it took into account the effect of infant prophylaxis and early childhood vaccination, as well as changing prevalence over time.
1.6K
Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030
Chris Estes,Quentin M. Anstee,María Teresa Arias-Loste,Heike Bantel,Stefano Bellentani,Joan Caballería,Massimo Colombo,Antonio Craxì,Javier Crespo,Christopher P. Day,Yuichiro Eguchi,Andreas Geier,Loreta A. Kondili,Daniela C. Kroy,Jeffrey V. Lazarus,Rohit Loomba,Michael P. Manns,Giulio Marchesini,Atsushi Nakajima,Francesco Negro,Salvatore Petta,V. Ratziu,Manuel Romero-Gómez,Arun J. Sanyal,Jörn M. Schattenberg,Frank Tacke,Junko Tanaka,Christian Trautwein,Lai Wei,Stefan Zeuzem,Homie Razavi +30 more
TL;DR: NAFLD and NASH represent a large and growing public health problem and efforts to understand this epidemic and to mitigate the disease burden are needed, if obesity and DM continue to increase at current and historical rates.
1.6K
Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis
Bart J. Veldt,E. Jenny Heathcote,Heiner Wedemeyer,Juerg Reichen,W. Peter Hofmann,Stefan Zeuzem,Michael P. Manns,Bettina E. Hansen,Solko W. Schalm,Harry L.A. Janssen +9 more
TL;DR: It was found that sustained virologic response decreased patients' hazard of liver failure and was associated with a reduction in fibrosis in patients with chronic hepatitis C and advanced fibrosis who did and did not have sustained virolic response to treatment.
633
2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B
Yun Fan Liaw,Edward Gane,Nancy Leung,Stefan Zeuzem,Yuming Wang,Ching-Lung Lai,E. Jenny Heathcote,Michael P. Manns,Natalie Bzowej,Junqi Niu,Steven Han,Seong Gyu Hwang,Yilmaz Cakaloglu,Myron J. Tong,George V. Papatheodoridis,Yagang Chen,Nathaniel A. Brown,Efsevia Albanis,Karin Galil,Nikolai V. Naoumov +19 more
TL;DR: Telbvudine is superior to lamivudine in treating patients with chronic hepatitis B over a 2-year period, and multivariate logistic regression analyses identified telbivUDine treatment, among other variables, as an independent predictor of better week 104 outcomes.
599